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Intensive insulin therapy is the best treatment for improving glycemic control to
prevent the progression of diabetic microvascular complication;
1 however, most
type 2 diabetes patients prefer fewer daily injections to the separate use of bolus
and basal components. Therefore, twice-daily injections of a mix type of insulin
or a single-daily injection of long-acting insulin is widely used for diabetes. In
addition, fewer daily insulin treatments can achieve good glycemic control similar
to that achieved with intensive insulin therapy in patients with type 2 diabetes.
2
UK Prospective Diabetes Study (UKPDS) proved that intensive treatment pre-
vented diabetic microangiopathy complications independent of insulin usage.
3
Therefore, it is important to achieve good glycemic control regardless of multiple
or single insulin usage. 
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Purpose: Premixed insulin is effective to improve glycemic control; however,
clinicians may be less likely to know which premixed insulin is appropriate for
which patients. This study aimed to evaluate the effects of twice-daily injections of
premixed insulin lispro on glycemic control in type 2 diabetic patients. Materials
and Methods: Forty type 2 diabetic patients, who had been treated with twice-
daily injections of human protamine mixture 30/70 insulin for at least 12 months,
were divided into two groups; one group whose blood glucose 2 hours after
breakfast was greater than 200 mg/dL, was switched to lispro mix50, and the other
group whose blood glucose 2 hours after breakfast < 200 was switched to lispro
mix25. Results: Glycated haemoglobin (HbA1c) significantly improved in the
Mix50 group from 8.3% to 7.5% (at 12 weeks; p < 0.05), and to 7.5% (at 24
weeks; p < 0.05). On the other hand, HbA1c levels in the Mix25 group were
slightly decreased from 8.1% to 7.7% at 12 weeks (p < 0.05), and to 7.9% at 24
weeks (not significant). Both postprandial plasma glucose and fasting plasma
glucose levels were significantly improved in the Mix50 group, but not in the
Mix25 group. Overall, 95% of subjects preferred premixed lispro insulin from
human insulin in the viewpoint of the timing of insulin injection by questionnaire
analysis. Conclusion: Switching from human protamine mixture 30/70 insulin to
lispro mix50 twice-daily injection therapy in patients with high postprandial
plasma glucose could improve their glycemic control and quality of life. 
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INTRODUCTIONHumalog Mix25 (Mix25), a manufactured premixed
insulin analogue containing 25% lispro insulin and 75%
basal component insulin lispro-protamine, and humalog
Mix50 (Mix50) containing 50% lispro and 50% NPL are
widely used as a twice-daily insulin regimen.
4 Compared
to the human insulin mixture, twice-daily injection of Mix25
or Mix50 provided improved glycemic control with a more
convenient injection just before a meal.
5-7 In addition, twice-
daily Mix25 therapy was reported to achieve better glyce-
mic control than basal insulin (glargine) therapy;
8 however,
it is difficult to make appropriate use of Mix25 and Mix 50
for particular subjects.
In the present study, we examined the effects of two
premixed analog insulins Mix25 and Mix50, by changing
over from human protamine mixture 30/70 treatment.
Theoretically, we switched according to the postprandial
glucose level, to Mix25 for subjects with below 200 mg/dL
and to Mix50 for subjects with greater than 200 mg/dL
serum glucose.
We enrolled 40 patients attending Dokkyo Medical Uni-
versity Hospital with type 2 diabetes and an glycated
haemoglobin (HbA1c) greater than 7.5%, who had been
receiving twice-daily injections of human protamine mix-
ture 30/70 insulin therapy for at least 12 months. We exclud-
ed patients who had a stroke or cardiovascular event history.
Hypoglycemic, anti-hypertensive and lipid-lowering
medications were not changed during this study. The study
protocol was approved by the institutional review board.
All patients gave informed consent to be included in this
study. The study was performed according to the guide-
lines in the Declaration of Helsinki. 
Subjects were divided into two groups: the first group,
whose postprandial plasma glucose levels (2 hours after
breakfast) were greater than 200 mg/dL, was switched to
lispro Mix50 (Mix50 group; n = 20); the other, whose
postprandial plasma glucose levels were below 200
mg/dL, was switched to lispro Mix25 (Mix25 group, n =
20). Patient characteristics are shown in Table 1. The
dosage of insulin were not changed for the first 12 weeks,
but were then adjusted to achieve adequate blood glucose
(< 180 mg/dL at 2 hours after breakfast in the hospital and
< 130 mg/dL at fasting) for the next 12 weeks. Dietary
education of diabetes was performed for 3 months before
switching to premixed insulin analog. A 400 to 500 kcal
meal was indicated for breakfast on the day when the
patients visited the hospital. We measured fasting and 120-
min postprandial levels of plasma glucose and blood
HbA1c. Plasma glucose was measured by the glucose
oxidase method (Medica Japan, Konosu, Japan). Blood
HbA1c levels were determined by high-performance liquid
chromatography (HPLC; Hi-auto A1c, HA8150; Arkray
Inc., Kyoto, Japan). 
After 12 weeks of treatment, to determine whether the
patients feel their ideal time of insulin injections are con-
venient, we conducted a questionnaire survey. Responses
were analyzed using a 10-point scoring system ranging
from -5 (convenient timing is 30 minutes before a meal) to
+5 (convenient timing is just before a meal) points.
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MATERIALS AND METHODS
Table 1.Clinical Characteristics of the Mix25 and Mix50 Groups 
Mix25 Mix50
Number (male/female) 20 (8 / 12) 20 (8 / 12)
Age (yrs) 61.0 ± 8.6 60.0 ± 14.2
Body weight (kg) 59.1 ± 10.6 59.1 ± 12.8
Diabetes duration (yrs) 12.7 ± 5.4 11.1 ± 5.5
Insulin treatment duration (yrs) 5.4 ± 3.1 4.9 ± 3.1
HbA1c (%) 8.1 ± 0.9 8.3 ± 0.9
Fasingplasma glucose (mg/dL) 150.7 ± 36.4 143.0 ± 34.0
Postprandial plasma glucose (mg/dL) 181.8 ± 19.3 228.8 ± 27.9*
Complications
Retinopathy 12 11
Nephropathy 15 15
Neuropathy 7 8
Hypertention 12 13
Hyperlipidemia 11 10
Cardiocascular disease 4 4
Values are given as the Mean ±SD. 
*p< 0.05 vs. Mix25 groups.Effect of Insulin Lispro Mix50 and Mix25
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Statistical analysis 
All data were analyzed with JMP
®7. The results are pre-
sented as the mean ± S.D. To compare the two groups we
carried out unpaired t-test or the Mann-Whitney U-test for
continuous variables, and the χ 2-test or Fisher test for quali-
tative variables. Two-tailed p values less than 0.05 were
considered significant.
In the Mix25 group, mean HbA1c levels did not change
over the 12 weeks before switching; however, they were
significantly decreased from 8.1% to 7.7% at 12 weeks (p
= 0.003). However, there were changed to 7.9% at 24 weeks
(p = 0.14), which was not significant (Table 2). Fast-ing
plasma glucose and postprandial plasma glucose (2 after
breakfast) were not significantly changed at either 12 or 24
weeks (Fig. 1). 
In the Mix50 group, mean HbA1c levels did not change
over the 12 weeks before switching; however, they were
significantly improved from 8.3% to 7.5% at 12 weeks (p
= 0.006), and to 7.5% at 24 weeks (p = 0.006) (Table 2).
Fasting plasma glucose was significantly decreased from
143.0 ± 34.0 to 133.3 ± 30.5 mg/dL (p = 0.03) at 12 weeks,
but remained unchanged at 134.8 ± 27.9 mg/dL at 24
weeks (p = 0.13) (Fig. 1). Postprandial plasma glucose was
significantly improved from 228.8 ± 27.9 to 189.4 ± 44.3
mg/dL at 12 weeks (p < 0.001) and to 182.5 ± 41.1 mg/dL
at 24 weeks (p< 0.001) (Fig. 1).
No significant changes were seen in body weight in the
Mix25 group from 59.1 ± 10.6 to 59.3 ± 10.4 kg at 24
weeks, whereas the body weight of the Mix50 group
increased from 59.1 ± 12.8 to 60.0 ± 13.5 kg (p = 0.003)
(Table 2). There were no reported adverse reactions, such
as severe hypoglycemia, during the study.
After 12 weeks of treatment, we asked the patients
whether their ideal time of insulin injection is just before a
meal or 30 minutes before a meal by a questionnaire
survey. They were analyzed using a 10-point scoring
system ranging from - 5 to + 5 points. The mean scoring
was 3.5 ± 2.3; in detail, 38 patients answered that an
injection just before a meal was convenient, and only 2
patients preferred an injection 30 minutes before a meal (- 4
and - 3 point) because they were used to preparing for
meals and self-monitoring glucose at this time.
Our findings indicated that Mix50 treatment showed better
glucose control than human 30/70 insulin therapy, especi-
DISCUSSION
RESULTS
Table 2.Change in HbA1c, Body Weight and Insulin Dose
-12 0 12 24 (week)
HbA1c (%) Mix25 8.0 ± 1.0 8.1 ± 0.9 7.7 ± 0.8* 7.9 ± 1.0
Mix50 8.2 ± 0.8 8.3 ± 0.9 7.5 ± 0.8* 7.5 ± 0.8*
Body weight (kg) Mix25 59.1 ± 10.9 59.1 ± 10.6 59.2 ± 10.6 59.3 ± 10.4
Mix50 59.2 ± 12.1 59.1 ± 12.8 59.5 ± 13.0 60.0 ± 13.5*
Insulin dose (unit/kg/day) Mix25 0.43 ± 0.21 0.43 ± 0.21 0.44 ± 0.20 0.45 ± 0.21
Mix50 0.46 ± 0.18 0.46 ± 0.17 0.45 ± 0.17 0.45 ± 0.17
Values are given as the mean ±SD. 
*p< 0.05 vs. the data at 0 week (switching).
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Fig. 1. Effects of Mix25 and Mix50 treatment on fasting and postprandial plasma glucose. Values are the mean ± SD. *p< 0.05 vs. baseline. PG,
plasma glucose; PPG, postprandial plasma glucose; FPG, fasting plasma glucose. ally in patients with high postprandial glucose levels. In
addition, changing from premixed human insulin 30/70 to
Mix50 provided better postprandial a fasting plasma
glucose, resulting in improved HbA1c levels. The possibil-
ity of decreasing fasting plasma glucose by changing to
Mix50 treatment was that glucose toxicity may be reduced
by decreasing postprandial glucose; therefore, endogenous
insulin secretion might recover,
9 although the plasma c-
peptide was not assessed in this study. Yamada, et al.
10
proved that twice-daily injections of Mix50 could achieve
better glucose control rather than premixed human insulin
(30/70 and 50/50) in type 2 diabetes patients. Moreover,
our study subjects were Japanese, whose main meal has a
high glycemic index, such as rice. This is one reason why
Mix50 treatment showed better glycemic control than
human 30/70 treatment. Roach, et al.
11 demonstrated that the
greater proportion of rapid-acting insulin analog was more
effective for carbohydrate-rich meals. It was reported that a
regimen of humalog Mix50 administered three times daily
before each meal maintains better glucose control than
premixed human insulin 30/70 administered before
breakfast and dinner.
12 From our findings, we think that a
regimen of humalog Mix50 administered twice-daily
should be considered before stepping up to three-daily
injections. 
The predominant effects of Mix25 on glucose control
have been reported compared to premixed human insulin
30/70.
4 In particular, Mix25 decreased the postprandial
glucose level better than premixed human insulin 30/70.
6,13
The present study showed that overall blood glucose
control was significantly improved 12 weeks after the
changeover, but not at 24 weeks. Moreover, no change of
fasting plasma glucose and postprandial plasma glucose (2
hours after breakfast) was observed in this study. One
possibility is that faster blood glucose after breakfast could
be inhibited by changing from human 30/70 insulin to
Mix25. The other possibility is that postprandial blood
glucose levels in the Mix25 group was not so high (< 200
mg/dL); therefore, the effect of Mix25 on postprandial
glucose could not been observed clearly.
Previous studies have shown that insulin treatment for
type 2 diabetes patients induced a body weight gain of 3%
to 9%, depending on the study duration, diabetic control
and insulin type.
14 Our findings indicated that only switching
from premixed human insulin 30/70 to premixed Mix50
increased by the mean baseline weight of approximately
1.6% for 24 weeks of treatment, whereas the Mix25
groups did not show any weight gain.
There were several study limitations in the present
examination. One of the limitations of our present study
was that the diurnal plasma glucose measurement was not
performed in the outpatient setting, and therefore, the
effect of changing insulin treatment on diurnal plasma
glucose change was not fully assessed. In addition, two
points of glucose measurement on the day when the pa-
tients visited the hospital may not provide enough informa-
tion as a glucose control. Also, glucose values may be
modified with food consumption the day before. Further
studies using self monitoring of blood glucose or the same
meal tolerance test are needed to elucidate the effects of
premixed insulin on postprandial levels of plasma glucose.
Second, our study design was only a changeover from
human insulin 30/70 to premixed Mix25 or Mix50 select-
ed based on postprandial plasma glucose levels (2 hours
after breakfast). Although this selection was simple, the
difference of diabetic severity and endogenous insulin
secretion between the two groups was not considered in
the selection. Therefore, if a subsequent crossover study
had been done, the effect of premixed Mix25 and Mix50
insulin could be compared directly in the same patients.
In conclusion, twice-daily injections of Mix50 compared
to human insulin 30/70 resulted in improved fasting and
postprandial blood glucose and overall HbA1c. In addi-
tion, mixed lispro insulin therapy offered a more conve-
nient injection time just before meals than human insulin
therapy.
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